Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.
ApexOnco Front Page
Recent articles
The companies press on with vilastobart and IMPT-314... up to a point.
The synthetic lethality specialist licenses in its second ADC in six months.
Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.
US approval gives Pfizer the first and second-line settings.
But, like Merck two weeks ago, GSK has failed to hit overall survival.
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
